SAN FRANCISCO, May 3, 2011 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Cellmid Ltd. (ASX: CDY) (the "Company") with a twelve month target price of AUD $0.10. Ross Silver, Principal Analyst at Vista Partners stated, "We believe Cellmid represents a significant value proposition to a potential collaborator considering the breadth of the Company's midkine ("MK") patents. The size of the market its therapeutics could compete, if approved, is in excess of $15 billion." Mr. Silver continued, "Cellmid has a large portfolio of patents surrounding MK and owns 21 patent families worldwide. Cellmid plans to monetize this portfolio through two segments: Diagnostics and Therapeutics. The diagnostic programs are in a more advanced stage and are poised to face regulatory approvals first. The therapeutic programs are in pre-clinical trials; however they involve high value antibody candidates with early partner/licensing potential." Mr. Silver concluded, "Cellmid is the second Australian biotechnology company we have covered, the previous Australian biotech company we covered was named Arana and they were acquired by Cephalon (ticker: CEPH) for $318M in 2009."
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.Disclaimer & Disclosure: For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here. Contact:877.215.4813 or firstname.lastname@example.org SOURCE Vista Partners
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV